QUÉBEC CITY, Oct. 11, 2012
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that it has commenced an
underwritten public offering of units (the "Offering"), consisting
of common shares and warrants to purchase common shares.
Roth Capital Partners, LLC, is acting as the sole book-running
manager for the Offering. The Offering is subject to market
conditions and there can be no assurance as to whether or when the
Offering may be completed, or as to the actual size or terms of the
Offering.
The Offering is being conducted pursuant to the Company's
effective shelf registration statement on Form F-10 filed with the
U.S. Securities and Exchange Commission (the "SEC"), its
corresponding Canadian base shelf prospectus and an exemption from
the Autorité des marchés financiers permitting the Company
to offer common shares and warrants in the United States. A preliminary prospectus
supplement relating to the offering will be filed with the SEC and
with the securities regulatory authority in each of the provinces
of Canada. When available, a copy
of the preliminary prospectus supplement and the accompanying base
shelf prospectus can be obtained on the SEC's website at
www.sec.gov or on the SEDAR website maintained by the Canadian
Securities Administrators at www.sedar.com. Alternatively, copies
of the preliminary prospectus supplement and the accompanying base
shelf prospectus may be obtained upon request by contacting Roth
Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA, 92660, (800) 678-9147,
e-mail: rothecm@roth.com.
This press release does not and shall not constitute an
offer to sell or the solicitation of an offer to buy any of the
Company's securities, nor shall there be any sale of the Company's
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information please visit
www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbour provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the risk that safety and efficacy data from any of our
Phase 3 trials may not coincide with the data analyses from
previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities
in the pharmaceutical industry, uncertainties related to the
regulatory process and general changes in economic conditions.
Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation
to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained
herein to reflect future results, events or developments, unless
required to do so by a governmental authority or by applicable
law.
SOURCE AETERNA ZENTARIS INC.